BZAM Past Earnings Performance
Past criteria checks 0/6
BZAM has been growing earnings at an average annual rate of 10.4%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 54.1% per year.
Key information
10.4%
Earnings growth rate
30.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 54.1% |
| Return on equity | -130.4% |
| Net Margin | -129.2% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How BZAM makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 82 | -106 | 43 | 0 |
| 30 Jun 23 | 71 | -97 | 39 | 0 |
| 31 Mar 23 | 63 | -40 | 34 | 0 |
| 31 Dec 22 | 49 | -35 | 29 | 0 |
| 30 Sep 22 | 42 | -33 | 26 | 0 |
| 30 Jun 22 | 39 | -40 | 28 | 0 |
| 31 Mar 22 | 35 | -66 | 28 | 0 |
| 31 Dec 21 | 30 | -39 | 28 | 0 |
| 30 Sep 21 | 28 | -48 | 27 | 1 |
| 30 Jun 21 | 23 | -109 | 26 | 1 |
| 31 Mar 21 | 15 | -85 | 26 | 1 |
| 31 Dec 20 | 13 | -171 | 35 | 1 |
| 30 Sep 20 | 9 | -301 | 48 | 1 |
| 30 Jun 20 | 9 | -246 | 61 | 2 |
| 31 Mar 20 | 11 | -254 | 71 | 2 |
| 31 Dec 19 | 11 | -195 | 72 | 2 |
| 30 Sep 19 | 10 | -69 | 70 | 2 |
| 30 Jun 19 | 7 | -60 | 58 | 2 |
| 31 Mar 19 | 4 | -52 | 49 | 3 |
| 01 Jan 19 | 2 | -45 | 41 | 3 |
| 30 Sep 18 | 0 | -33 | 29 | 3 |
| 30 Jun 18 | 0 | -24 | 22 | 3 |
| 31 Mar 18 | 0 | -18 | 17 | 2 |
| 31 Dec 17 | 0 | -13 | 14 | 1 |
Quality Earnings: BZAM.F is currently unprofitable.
Growing Profit Margin: BZAM.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BZAM.F is unprofitable, but has reduced losses over the past 5 years at a rate of 10.4% per year.
Accelerating Growth: Unable to compare BZAM.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BZAM.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: BZAM.F has a negative Return on Equity (-130.4%), as it is currently unprofitable.